Increasing use of atypical antipsychotics and anticonvulsants during pregnancy

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 7, 2013, Pages 794-801

  Epstein, Richard A ^a   Bobo, William V ^a   Shelton, Richard C ^a   Arbogast, Patrick G ^a   Morrow, James A ^a   Wang, Wei ^a   Chandrasekhar, Rameela ^a   Cooper, William O ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticonvulsants; Antipsychotics; Fetal effects; Lithium; Pharmacoepidemiology; Pregnancy

Indexed keywords

ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; LITHIUM; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; DEPRESSION; DRUG USE; EPILEPSY; FEMALE; FETUS DEATH; HUMAN; LIVE BIRTH; MONOTHERAPY; PAIN; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA;

ANTICONVULSANTS; ANTIPSYCHOTICS; FETAL EFFECTS; LITHIUM; PHARMACOEPIDEMIOLOGY; PREGNANCY;

ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; DRUG UTILIZATION REVIEW; FEMALE; GUIDELINE ADHERENCE; HUMANS; LINEAR MODELS; MEDICAID; MENTAL DISORDERS; PHARMACOEPIDEMIOLOGY; PHARMACOVIGILANCE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 84879553315     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3366     Document Type: Article

References (53)

1. Citrome L, Jaffe A, Levine J, Allingham B. Use of mood stabilizers among patients with schizophrenia, 1994-2001. Psychiatr Serv 2002; 53: 1212.
2. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166: 980-991.
3. Glick ID, Murray SR, Vasudevan P, Marder SR, Hu RJ. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res 2001; 35: 187-191.
4. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006; 166: 1021-1026.
5. Chen H, Deshpande AD, Jiang R, Martin BC. An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population. Pharmacoepidemiol Drug Saf 2005; 14: 629-638.
6. Cooper WO, Arbogast PG, Ding H, Hickson GB, Fuchs DC, Ray WA. Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr 2006; 6: 79-83.
7. Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med 2004; 158: 753-759.
8. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. Feb 2011; 20(2): 177-184.
9. Olfson M, Marcus SC, Weissman MM, Jensen PS. National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry May 2002; 41(5): 514-521.
10. Cooper WO, Federspiel CF, Griffin MR, Hickson GB. New use of anticonvulsant medications among children enrolled in the Tennessee Medicaid Program. Arch Pediatr Adolesc Med 1997; 151(12): 1242-1246.
11. Werler MM, Ahrens KA, Bosco JL, et al. Use of antiepileptic medications in pregnancy in relation to risks of birth defects. Ann Epidemiol. Nov 2011; 21(11): 842-850.
12. Gilboa SM, Broussard CS, Devine OJ, et al. Influencing clinical practice regarding the use of antiepileptic medications during pregnancy: modeling the potential impact on the prevalences of spina bifida and cleft palate in the United States. Am J Med Genet. Part C, Seminars in medical genetics. Aug 15 2011; 157(3): 234-246.
13. Viguera AC, Cohen LS, Baldessarini RJ, Nonacs R. Managing bipolar disorder during pregnancy: weighing the risks and benefits. Can J Psychiatry. Jun 2002; 47(5): 426-436.
14. Gentile S. Clinical utilization of atypical antipsychotics in pregnancy and lactation. Ann Pharmacother. Jul-Aug 2004; 38(7-8): 1265-1271.
15. Cohen LS. Treatment of bipolar disorder during pregnancy. J Clin Psychiatry 2007; 68(Suppl 9): 4-9.
16. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77: 193-198.
17. Perucca E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol 2005; 4: 781-786.
18. Reis M, Kallen B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 2008; 28: 279-288.
19. Samren EB, van Duijn CM, Christiaens GC, Hofman A, Lindhout D. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999; 46: 739-746.
20. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19(Suppl 1): 1-93.
21. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. Nov 24 2000; 68(1): 29-39.
22. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. Oct 1989; 251(1): 238-246.
23. U. S. Food and Drug Administration. FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm. [August 22, 2011].
24. U. S. Food and Drug Administration. Information for healthcare professionals: Risk of neural tube birth defects following prenatal exposure to valproate. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm192649.htm. [August 22, 2011].
25. U. S. Food and Drug Administration. FDA: Risk of oral birth defects in children born to mothers taking topiramate. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm245594.htm. [August 22, 2011].
26. Piper JM, Mitchel EF, Jr., Snowden M, Hall C, Adams M, Taylor P. Validation of 1989 Tennessee birth certificates using maternal and newborn hospital records. Am J Epidemiol 1993; 137: 758-768.
27. Cooper WO, Ray WA, Griffin MR. Prenatal prescription of macrolide antibiotics and infantile hypertrophic pyloric stenosis. Obstet Gynecol 2002; 100: 101-106.
28. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354: 2443-2451.
29. The Kaiser Family Foundation. 2010. Maternal and child health update: States make progress towards improving systems of care, National Governors Association, Table6. 2010. http://www.nga.org/files/live/sites/NGA/files/pdf/MCHUPDATE2010.PDF. [May 22, 2012].
30. Ray WA, Gigante J, Mitchel EF, Jr., Hickson GB. Perinatal outcomes following implementation of TennCare. JAMA 1998; 279: 314-316.
31. Piper JM, Mitchel EF, Jr., Ray WA. Expanded Medicaid coverage for pregnant women to 100 percent of the federal poverty level. Am J Prev Med. Mar-Apr 1994; 10(2): 97-102.
32. Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol 1989; 129: 837-849.
33. West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995; 142: 1103-1112.
34. Hamilton RJ (ed.). Tarascon Pocket Pharmacopoeia: 2009 Deluxe Lab-Coat Pocket Edition. Jones and Bartlett: Boston, 2009.
35. Meltzer HY, Bobo WV. Antipsychotic and anticholinergic drugs. In Textbook of Psychiatry, Vol 2 (2nd edn), MG Gelder NA, Lopez-Ibor JJ, Geddes JR (eds). Oxford University Press: New York, 2009.
36. American Psychological Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. Apr 2002; 159(4 Suppl): 1-50.
37. Ketter TA, Wang PW, Nowakowska C, Marsh WK, Bonner J. Treatment of acute mania in bipolar disorder. In Advances in treatment of bipolar disorder, Ketter TA (ed.). American Psychiatric Publishing: Washington, D.C., 2005; 11-56.
38. Mazza M, Di Nicola M, Martinotti G, et al. Oxcarbazepine in bipolar disorder: a critical review of the literature. Expert Opin Pharmacother 2007; 8: 649-656.
39. Fullerton CA, Busch AB, Frank RG. The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion. Med Care 2010; 48: 372-379.
40. Chouinard G. The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs. J Psychiatry Neurosci 2006; 31: 168-176.
41. Gajwani P, Forsthoff A, Muzina D, et al. Antiepileptic drugs in mood-disordered patients. Epilepsia 2005;46(Suppl 4):38-44.
42. Muzina DJ, Elhaj O, Gajwani P, Gao K, Calabrese JR. Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder. Acta Psychiatr Scand Suppl 2005; 426: 21-28.
43. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol. May 2011; 10(5): 446-456.
44. Selph S, Carson S, Fu R, Thakurta S, Low A, McDonagh M. Drug class review: Neuropathic pain. Update 1 final report. Oregon Health & Science University: Portland, OR, 2011.
45. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. Feb 2004; 161(2 Suppl): 1-56.
46. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. May 2009; 11(3): 225-255.
47. Fleurence R, Williamson R, Jing Y, et al. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull 2009; 42(3): 57-90.
48. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord International Epilepsy Journal With Videotape. Jun 2004; 6(2): 57-75.
49. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. Sep 28 2011; 306(12): 1359-1369.
50. Comai S, Tau M, Pavlovic Z, Gobbi G. The psychopharmacology of aggressive behavior: a translational approach: part 2: clinical studies using atypical antipsychotics, anticonvulsants, and lithium. J Clin Psychopharmacol Apr 2012; 32(2): 237-260.
51. Wilcosky TC, Chambless LE. A comparison of direct adjustment and regression adjustment of epidemiologic measures. J Chronic Dis 1985; 38: 849-856.
52. Dupont WD. Statistical Modeling for Biomedical Researchers. 2nd Edition. Cambridge University Press: Cambridge, 2009.
53. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria, 2012.